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Abstract
Background: Early mortality for HIV-positive people starting antiretroviral therapy (ART) remains high in resource-limited
settings, with tuberculosis the most important cause. Existing rapid diagnostic tests for tuberculosis lack sensitivity among
HIV-positive people, and consequently, tuberculosis treatment is either delayed or started empirically (without
bacteriological confirmation). We developed a management algorithm for ambulatory HIV-positive people, based
on body mass index and point-of-care tests for haemoglobin and urine lipoarabinomannan (LAM), to identify
those at high risk of tuberculosis and mortality. We designed a clinical trial to test whether implementation of this
algorithm reduces six-month mortality among HIV-positive people with advanced immunosuppression.
Methods/design: The TB Fast Track study is an open, pragmatic, cluster randomised superiority trial, with 24
primary health clinics randomised to implement the intervention or standard of care. Adults (aged ≥18 years)
with a CD4 count of 150 cells/μL or less, who have not received any tuberculosis treatment in the last three
months, or ART in the last six months, are eligible. In intervention clinics, the study algorithm is used to classify
individuals as at high, medium or low probability of tuberculosis. Those classified as high probability start
tuberculosis treatment immediately, followed by ART after two weeks. Medium-probability patients follow the
South African guidelines for test-negative tuberculosis and are reviewed within a week, to be re-categorised as
low or high probability. Low-probability patients start ART as soon as possible. The primary outcome is all-cause
mortality at six months. Secondary outcomes include severe morbidity, time to ART start and cost-effectiveness.
Discussion: This trial will test whether a primary care-friendly management algorithm will enable nurses to identify
HIV-positive patients at the highest risk of tuberculosis, to facilitate prompt treatment and reduce early mortality. There
remains an urgent need for better diagnostic tests for tuberculosis, especially for people with advanced HIV disease,
which may render empirical treatment unnecessary.
Trial registration: This trial was registered with Current Controlled Trials (identifier: ISRCTN35344604) on 12
September 2012.
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Background
Background and rationale
Early mortality among HIV-positive people starting
antiretroviral therapy (ART) remains higher in resource-
constrained settings compared with industrialised coun-
tries [1]. Tuberculosis is the most important cause of
death among people with HIV worldwide [2], and limited
data suggest that this remains true of people starting ART
[3]. However, the diagnosis of tuberculosis is difficult
and may be missed altogether, particularly among
people with low CD4 counts, who are less likely to be
diagnosed using sputum-based tests because of lower
mycobacterial concentration or inability to produce
sputum, and may have atypical appearances on chest
radiography. Sputum mycobacterial culture is the gold
standard diagnostic test for tuberculosis, but is not rou-
tinely available in many resource-constrained settings.
Where culture is available, the result may take up to six
weeks, which may delay ART initiation [4].
New diagnostic tests for tuberculosis are increasingly
available. In South Africa, Xpert MTB/RIF has replaced
sputum microscopy as the first diagnostic test for tuber-
culosis [5]. With an instrument turnaround time of
under two hours, Xpert MTB/RIF has the potential to
provide point-of-care testing with in-session results, but
the instrument requirements, its moderate complexity
[6,7] and high cost mean that it is unlikely to be widely
implemented at primary care level in resource-
constrained settings. Xpert MTB/RIF has better sensitiv-
ity than microscopy, but is less sensitive than sputum
culture on liquid media [8]. Further, in two trials com-
paring Xpert MTB/RIF to sputum smear microscopy,
Xpert did not improve patient-relevant outcomes. In the
XTEND trial, nested within national roll-out of Xpert
MTB/RIF in South Africa, placed in off-site laboratories,
there was no reduction in mortality among people being
investigated for tuberculosis [9]. In the TB-NEAT trial
Xpert MTB/RIF was deployed in primary care clinics to
give a same-day result, with no resulting reduction in
morbidity [10]. In both trials, a likely explanation was
that many people were treated empirically (that is, with-
out microbiological confirmation) for tuberculosis, and
that Xpert MTB/RIF provided microbiological confirm-
ation for some cases which would otherwise have been
treated empirically, but found few additional cases.
Empirical treatment of tuberculosis is common, but
often requires a physician’s decision. Many primary care
clinics are run by nurses with physicians attending only
occasionally, if at all, and in such settings empirical treat-
ment may be delayed, or not initiated. We sought to de-
velop an algorithm which would enable nurses in primary
care settings to identify, among HIV-positive people with
advanced immunosuppression who are at high risk of
death, those at the highest risk of tuberculosis, in order to
start empirical tuberculosis treatment promptly, followed
by ART.
A promising candidate component of this algorithm was
an assay for lipoarabinomannan (LAM), a mycobacterial
cell-wall component which can be detected in urine
among patients with tuberculosis. A lateral flow assay for
LAM is commercially available as a point-of-care test, giv-
ing a result in 25 minutes at relatively low cost which, with
no requirement for sample processing, has potential for
use in primary care clinics. The test’s sensitivity is too low
to be useful for HIV-negative people. Even among HIV-
positive people, sensitivity is inadequate, except among
those with very low CD4 counts [11]. We therefore se-
lected two additional markers for our algorithm: body
mass index (BMI) and haemoglobin. Among people with
HIV, low BMI and low haemoglobin levels are strongly
associated with early mortality, and also with active tuber-
culosis [12-17]. Both BMI and haemoglobin can be mea-
sured by a nurse in a primary care setting with in-session
results. Additional analysis of data from a study evaluating
LAM among hospitalised patients in South Africa with
signs or symptoms of tuberculosis [18] helped refine the
algorithm.
We therefore decided to evaluate an algorithm com-
bining haemoglobin, BMI and urine LAM lateral flow
assay with symptom screening for tuberculosis, to clas-
sify study patients as having high, medium or low prob-
ability of active tuberculosis (Figure 1), and accordingly
start presumptive tuberculosis treatment, ART or both,
with minimal delay.
Rationale for a randomised controlled trial
Our overall aim was to enable the rapid initiation of tu-
berculosis treatment among high-risk people, and thus
reduce early mortality due to tuberculosis. Rapid initi-
ation of tuberculosis treatment should also facilitate
early initiation of ART, thus reducing early mortality due
to a wide range of conditions associated with advanced
HIV disease. Other potential advantages include a lower
risk of morbidity associated with immune reconstitution
syndrome due to tuberculosis, reduced morbidity due to
rifampicin-sensitive bacterial infections and effective
treatment for latent tuberculosis infection.
However, a strategy promoting rapid initiation of tuber-
culosis treatment without bacteriological confirmation has
potential disadvantages. For patients, some will receive
tuberculosis treatment when they do not, in reality, have
active tuberculosis, with attendant risks of adverse effects
and drug interactions. Some patients with unidentified
drug-resistant tuberculosis may be inappropriately treated
with a regimen appropriate only for drug-sensitive tuber-
culosis. The focus of the algorithm on tuberculosis could
also delay investigation and treatment for alternative co-
morbidities. For the health system, disadvantages include
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a higher caseload of patients requiring tuberculosis treat-
ment, and an apparent increase in tuberculosis case no-
tification rates. Given uncertainties concerning whether
the expected benefits of our novel management algo-
rithm would outweigh the risks, we propose to conduct
a clinical trial.
Rationale for a cluster randomised trial
This trial could broadly be considered a health service
delivery trial; for such trials, there is debate about
whether randomisation should be at the individual or
cluster level [19,20]. Advantages of cluster randomisa-
tion include minimising contamination, in that where
patients in the same clinic are randomised to different
arms, elements of the intervention may be implemented
among patients allocated to the control arm. Other advan-
tages include logistical convenience and approximating
more closely how the intervention would be delivered in
routine practice. Disadvantages include a larger sample
size for the same power and effect size, complexities of re-
vising sample size calculations if necessary, challenges in
controlling for confounding and standardising delivery of
the intervention. We decided on randomisation at clinic
level primarily because we anticipated that contamination
would be likely if individuals in one clinic could be rando-
mised to either intervention or control arm.
Study enrolment
TB symptom screen 
Determine BMI; Hb; urine LAM 
Assess TB probability 
High probability TB 
any of: LAM positive, Hb<10; 
BMI<18.5 [or smear/GXP pos]  
Medium probability TB
(symptomatic, Hb>10, 
BMI>18.5, LAM negative) 
Start antibiotics 
Request CXR 
Routine sputum smear / culture 
Review within 1 week
symptoms, CXR, 
smear/GXP 
Low probability TB
based on symptoms,  
smear/GXP, CXR 
High probability TB 
based on symptoms, 
smear/GXP, CXR 
6 month post enrolment review (participant 
interview and notes review) 
[if not contactable at 6m , trace participant / 
designated contact check vs. national vital 
status records] 
Start AR TStart TB treatment 
±2 week review 
if stable on TB 
treatment, start ART 
Low probability TB 
no symptoms, Hb>10, BMI>18.5, 
LAM negative 
2 month notes review 
Figure 1 TB Fast Track management algorithm. ART: antiretroviral therapy; BMI: body mass index; CXR: chest radiograph; GXP: Xpert MTB/RIF;
Hb: haemoglobin; LAM: lipoarabinomannan (urine assay for tuberculosis); TB: tuberculosis.
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Hypothesis
We hypothesise that, for adults with HIV with a CD4
count of 150 cells/μL or less who are not taking ART, a
care pathway using point-of-care tests to rapidly identify
individuals at high risk of tuberculosis and ensure initi-
ation of tuberculosis treatment followed by ART, will re-
duce mortality within the six months following enrolment.
Methods/design
Study design
The study is an open, pragmatic two-arm cluster rando-
mised superiority trial, with primary health clinics as the
unit of randomisation. The intervention is integrated
into routine clinic activities as far as possible: study staff
implement the algorithm, and all other aspects of care
for the patient are delivered by clinic staff.
Intervention arm - implementation of the algorithm
The study nurse completes a questionnaire with consent-
ing, eligible patients to determine tuberculosis symptoms
and BMI, and performs point-of-care tests for haemoglo-
bin concentration and urine LAM (Determine™ TB LAM
Ag, Alere, Waltham Massachusetts, United States). Pa-
tients are then classified as having high, medium or low
probability of active tuberculosis (Figure 1).
Participants are classified as at a high probability of tu-
berculosis if they have: (i) a positive urine LAM result
(defined as any positive band on the test strip, graded
against the manufacturer’s pre-January 2014 reference
card), (ii) a haemoglobin concentration <10 g/dL or (iii)
a BMI <18.5 kg/m2 (along with any patient with a previ-
ous sputum smear or positive Xpert MTB/RIF test
[Cepheid, Sunnyvale, CA, USA] result). They are started
on tuberculosis treatment immediately, followed by ART
as soon as possible.
Participants classified as at a low probability of tubercu-
losis, defined as no symptoms suggestive of tuberculosis, a
negative LAM result, a haemoglobin concentration ≥10 g/
dL and a BMI ≥18.5 kg/m2 (and not known to be sputum
smear or Xpert MTB/RIF positive) are started on ART
(without tuberculosis treatment) as soon as possible.
Participants classified as at a medium probability of
tuberculosis, that is, reporting any symptom suggestive
tuberculosis but not satisfying the criteria for high prob-
ability, are managed in accordance with national guide-
lines for test-negative tuberculosis: given broad spectrum
(non-quinolone) antibiotics if indicated, an additional rou-
tine sputum sample is taken for smear and mycobacterial
culture in line with routine practice, and a chest radi-
ography is arranged if not recently performed, with re-
view within one week wherever possible. At review,
they are classified as high or low probability, based on
symptom review, response to antibiotic treatment and
investigation results.
Patients with specific symptoms suggesting diagnoses
other than tuberculosis are managed in accordance with
national guidelines. For study participants who start tu-
berculosis treatment, an efavirenz-based ART regimen is
used, to be compatible with tuberculosis treatment. Any
patients unable or unwilling to take this ART regimen
are excluded from the trial. Outside this situation, pa-
tients can take any ART regimen consistent with South
African ART guidelines.
In order to have a reference ‘gold standard’ against
which to assess the study algorithm, a sputum specimen
is also collected at enrolment for smear, culture, organ-
ism identification and drug susceptibly testing at a re-
search laboratory. Results are not available at the time of
enrolment, and so do not contribute to the initial assign-
ment of probability of tuberculosis.
Standard of care
Study staff recruit eligible, consenting patients and
complete a short questionnaire, measure height and
weight (for systematic measurement of BMI for analysis
purposes). Further assessment for tuberculosis and
preparation for ART is undertaken by clinic staff ac-
cording to routine practice following national guide-
lines. In both arms of the study, dried blood spots and
a urine sample are collected and stored. Intended tests
include cryptococcal antigen and culture of urine for
mycobacteria.
Selection of study clinics
The study is conducted in primary care clinics and com-
munity health centres in a mixture of urban and rural
settings in Gauteng, North West and Limpopo prov-
inces, South Africa. Exclusion criteria include having a
laboratory doing sputum smear microscopy and Xpert
MTB/RIF tests onsite, with same day results. There was
a deliberate decision to include rural sites on the basis
that the intervention is particularly relevant to patients
in rural settings, where long distances to clinics may be
a barrier to speedy initiation of ART, particularly if mul-
tiple visits are needed.
Study population
The study population are HIV-positive adults (≥18 years)
with a CD4 count of 150 cells/μL or less, who are willing
to start ART. The trial aims to be as generalisable as
possible so exclusion criteria are few and include, among
others, patients currently on tuberculosis treatment,
who have completed tuberculosis treatment in last three
months or ART in the last six months, those with a
contraindication to efavirenz and those who are too sick
to be managed in ambulatory care. We chose a CD4
count threshold of 150 cells/μL or less primarily because of
the high risk of mortality in this group. A more standard
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CD4 count cutoff of under 200 cells/μL would have made
the study more widely applicable, though at a cost of hav-
ing a larger sample size due to a lower mortality rate
among ART initiators with a CD4 count between 150 and
200 cells/μL.
Trial outcomes
The primary outcome is all-cause mortality measured
over a six-month period following enrolment. Secondary
outcomes are (i) duration of hospital admission in the
first six months after enrolment, (ii) time from enrol-
ment to ART start, (iii) proportion of patients retained
in HIV care and (iv) serious and severe adverse events in
specified categories as defined by the study (particularly
hepatotoxicity, hypersensitivity, peripheral neuropathy
and nephrotoxicity). The study has also defined eco-
nomic outcomes relating to measuring cost-effectiveness
which include total diagnostic cost of the study cohort
in intervention and control arms, as well as incremental
diagnostic, treatment and per disability-adjusted life year
(DALY) costs of the intervention compared to control
from a provider perspective, over the six-month follow-
up period.
Vital status at six months from enrolment will be
ascertained from patient interview and medical records,
and supplemented with information from the partici-
pant’s nominated next of kin for those lost to follow-up,
and the South African mortality registration for partici-
pants with a South African identification number. If ne-
cessary, a trial endpoints committee will be convened,
masked to study arm, to assign death endpoints where
there are discrepant dates of death. Secondary outcomes
will be measured using a combination of data from pa-
tient interview and medical records, abstracted at two
and six months from enrolment. A substudy among
study participants who die is being conducted, using
needle and verbal autopsy methods to ascertain causes
of deaths.
Economic evaluation
An economic evaluation is being conducted from a
provider perspective. The primary outcome for the eco-
nomic evaluation is incremental cost per death averted
within the trial period. An additional analysis will be
conducted to estimate incremental cost per DALY
averted. The costs of the intervention are being collected
throughout the trial period, with care taken to exclude
any research-related costs. A bottom-up costing ap-
proach will be used to measure the costs associated with
implementation of the point-of-care tests at the clinic
level (cost per person assessed and costs for different
components of the algorithm). Provider costs for all ser-
vices in the patient pathway are being collected from a
sample of six clinics, purposively selected based on the
ratio between staffing levels and the number of clinic at-
tendees. Patient-level data on health service use are being
collected using the general trial instruments (follow-up
visits) and case note data. Should the intervention be
found cost-effective, a budget impact analysis will be con-
ducted to estimate the costs of national scale-up.
Sample size considerations
Data from the TB and HIV Prevention, Care and Treat-
ment programme of The Aurum Institute helped inform
the sample size calculation for the primary outcome.
Mortality in the first six months after ART initiation
among those with a CD4 count of under 150 cells/μL
was 24/100 person-years [17,21,22]. For the sample size
calculation, this was considered a minimum estimate,
given that ascertainment of deaths did not include a
search of national death registrations for some of these
studies, and mortality prior to ART exceeds mortality
during ART. Given our study is designed to enrol pa-
tients prior to ART start we used a mortality estimate of
25/100 person-years in the standard of care arm. The
sample size calculation took into account the clustered
design [19] through the coefficient of variation, which
we assumed to be between 0.2 and 0.25. We had no pre-
study clinic-level mortality data to inform coefficient of
variation between clinics, but given the study population
were patients pre-ART, all with CD4 counts of 150 cells/
μL or less, we assumed a coefficient of variation no
greater than 0.25 was reasonable.
Tuberculosis is identified at autopsy in 21 to 54% of
HIV-positive adults in sub-Saharan Africa [2]. Given the
very high prevalence of tuberculosis in South Africa [3],
we assumed that 60% of early deaths in our study popu-
lation would be attributable to tuberculosis, and that,
through earlier initiation of tuberculosis treatment, 66%
of these could be averted. Using data from the TB and
HIV Prevention, Care and Treatment programme of The
Aurum Institute, among individuals with a CD4 count
between 100 and 150 cells/μL, a two-month delay in
ART initiation resulted in a 150% increase in mortality
by six months; from 7% with immediate ART initiation
to 18% if there was a two-month delay [22]. There must
be some overlap of preventable deaths between these
two effects, which we could not quantify precisely. Over-
all, we assumed that the intervention had the potential
to result in a 40% reduction in mortality by six months
after study enrolment.
Assuming 10 clinics per arm, 175 patients per clinic, 5%
individuals whose vital status could not be ascertained at
six months, estimated mortality of 25/100 person-years in
the standard of care arm and coefficients of variation of
0.2 and 0.25, there would be 91% and 85% power to assess
a 40% reduction in mortality, respectively. If the coefficient
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of variation is 0.2, there would be 81% power to assess a
35% reduction in mortality.
After enrolling participants for six months we estab-
lished that for some clinics, the target of 175 patients
per clinic was unlikely to be achieved, and so the sample
size calculations were revised. Assuming a harmonic
mean of 109 patients per clinic, by randomising an add-
itional four clinics, the study maintained similar power
and effect sizes as with the original calculation.
Randomisation
The initial randomisation of 20 clinics was based on re-
striction, common in cluster randomised trials with a
small number of clusters [19], and based on having rea-
sonable balance, separately, for mean CD4 count, peri-
urban/rural location of the clinic and the total number
of new ART initiations per month. Using these criteria,
11,160 (6.0%) of the 184,756 possible allocations for ran-
domising 20 clinics to two arms (ratio of 1:1) were iden-
tified. The validity of this restriction was checked for
each allocation by comparing the number of times a
cluster appeared in the same arm with each other clus-
ter. There was no extreme imbalance and this restriction
was assumed to be valid. The randomisation was orga-
nised by a statistician. In a public ceremony with study
clinics represented by clinic managers and other HIV
and TB programme staff, one allocation was chosen at
random. Due to the revision in sample size, a second
public randomisation took place 14 months later, where
four additional clinics were randomised in a ratio 1:1 to
the intervention or standard of care arm.
Data collection and management
Case report forms were piloted in 10 clinics prior to the
study start. Before a clinic formally initiated enrolment,
the enrolment, one-week and two-week case report
forms were tested in around 10 patients.
Written informed consent is obtained from all partici-
pants using information sheets available in relevant lan-
guages, with the assistance of a translator where necessary,
using standard consent forms. Participants unable to read
or write are asked to make a mark or thumbprint in the
presence of a witness. Following enrolment, participants in
the two arms are seen in accordance with the visit schedule
summarised in Table 1. Study staff complete case report
forms on carbonated paper in duplicate, and store forms at
site in locked filing cabinets, with access to these records
restricted to specified study team members. Case report
forms are identified using the participant’s study number
only, with locator information stored separately.
Participant retention is crucial for this study, in par-
ticular for the measurement of the primary outcome. At
enrolment in both arms, participants are asked to give
locator information, including next of kin and their
South African identification number, as described previ-
ously. Participants are also asked to provide their mobile
telephone number, and are called by study staff at one
week, and one, two, four and six months to reconfirm
contact details. Participants are encouraged to notify
study staff of any relevant changes in their circum-
stances, such as moving away from the locality.
A quality control system is in place to monitor 100%
of the consent forms and enrolment case report forms,
and 10% of follow-up case report forms. More frequent
monitoring of a site is initiated if problems are identi-
fied. Every week, across all 24 sites, the bottom copies of
completed forms are sent to a central office for data
entry in a password-protected, user-limited sequel data-
base, with range checks on fields where appropriate.
Queries based on data in the database are generated
every one to two months and sent to sites for resolution.
Data in the database from all case report forms from a
random sample of 10% of study participants are verified.
In addition, data on critical fields, primarily used for
measurement of study endpoints, are verified in the
database for 100% of study participants. Locator data are
stored separately from the main database.
Statistical analysis
Analyses will use methods appropriate for the cluster
randomised trial design, giving each cluster equal weight.
Quantitative outcomes will be summarised as the mean
for each cluster and the difference of means for the
intervention versus standard of care arm. For binary out-
comes or rate outcomes, the overall risk (rate) for each
cluster will be calculated, as well as the ratio for the
intervention versus standard of care arm. Given the
overall randomisation was conducted using two strata
(20 and four clinics in each stratum), the standard error
for each effect measure will take into account stratified
randomisation. An adjusted analysis will be conducted if,
after visual inspection, imbalance by study arm in
patient- or clinic-level factors is observed, to help reduce
variability across clinics with respect to primary and sec-
ondary outcomes.
Subgroup analyses will be conducted for the primary
outcome for baseline CD4 count (<50 or ≥50 cells/μL),
previous tuberculosis history (from self-report; no previous
or previous tuberculosis), baseline BMI (<18.5 or ≥18.5 kg/
m2) and baseline haemoglobin (<8 or ≥8 g/dL). A statistical
analysis plan documents the analysis of all trial outcomes.
Ethics and dissemination
The trial has approval from the Research Ethics Com-
mittees of the University of Witwatersrand (approval
number: R14/49 M111177); the London School of Hy-
giene and Tropical Medicine, United Kingdom (approval
number: 6099) and the Provincial Research Committees
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Table 1 Summary of study procedures
Intervention Control
Enrolment 1 week (or less) 2 weeks 1 month 2 months 4 months 6 months Enrolment 1 week (or less) 2 weeks 1 month 2 months 4 months 6 months
Informed consent √ √
Locator information √ √
Baseline questionnaire √ √
TB symptom screen √ √a √
Body mass index √ √
Lab tests
Haemoglobin √
Urine
lipoarabinomannan
√ √ a
Sputum TB microscopy
and culture
√
Urine/dried blood spot
for storage
√ √
TB patient follow-up
visit
√b
Patient record review √ √ √ √ √ √
6 month
questionnairec
√ √
Patient contact calls √ √ √ √ √ √ √ √ √ √
aFor those at medium probability of TB according to the study algorithm. bFor those started on TB treatment, to check if stable on TB treatment and ready to start antiretroviral therapy. cA subset of participants also
have this questionnaire repeated at 12 months from enrolment. TB, tuberculosis.
Fielding
et
al.Trials
 (2015) 16:125 
Page
7
of
11
of Gauteng, North West and Limpopo. It is registered with
the South African Medicines Control Council as a phase 4
clinical trial (identifier: N2/19/8/2 () #20120157), and with
Current Controlled Trials (identifier: ISRCTN35344604
[23]) and the South African registry (identifier: DOH-27-
0812-3902).
The trial results will be communicated to stakeholders
through dissemination meetings and to trial participants
using language-appropriate information sheets. Investi-
gators will present results at relevant conferences, and
submit manuscript(s) to peer-reviewed journals. Public
access to the participant-level dataset of main trial re-
sults and statistical code will be made available.
Trial governance
The trial is governed by the Trial Steering Committee
(TSC) and the Data Monitoring Committee (DMC). The
TSC oversees the trial, monitors its progress and re-
ceives reports from the DMC, and advises the Chief In-
vestigator and investigator team. The DMC’s role is to
protect and serve trial patients, to assist and advise the
Chief Investigator and the TSC so as to protect the val-
idity and credibility of the trial and monitor the overall
conduct of the clinical trial. The DMC meets approxi-
mately every six months, followed by a TSC meeting.
Protocol amendments are submitted to all ethics com-
mittees and communicated to all investigators, the TSC
and DMC.
Discussion
This study aims to evaluate whether early mortality can
be reduced, among ambulatory people with advanced
HIV disease not taking ART, by an algorithm which en-
ables nurses in primary care clinics to identify patients
at highest risk and rapidly start them on tuberculosis
treatment. A number of other recent trials, summarised
in Table 2, aim to address the problem of high early
mortality among people with advanced HIV disease en-
tering care. The PrOMPT [24] and REMEMBER [25]
studies aimed to evaluate empirical tuberculosis treat-
ment among people with HIV and very low CD4 counts
who screened negative for active tuberculosis at study
entry. Recruitment to the PrOMPT study was much
slower than anticipated and as a result the study was dis-
continued. The REMEMBER trial, with sites in Brazil,
Haiti, India, Peru and five African countries, has a pri-
mary outcome of mortality at 24 weeks. Recruitment is
complete and results are expected in 2015. The STATIS
trial compares, among people with no overt evidence of
tuberculosis at study entry, empirical tuberculosis treat-
ment to intensive investigation for tuberculosis among
HIV-positive patients with a CD4 count under 100 cells/
μL in Cambodia, Côte d’Ivoire, Uganda and Vietnam
[26]. Intensive investigation comprises Xpert MTB/RIF,
urine LAM tests and a chest radiograph at baseline and
at every follow-up visit, with tuberculosis treatment
guided by these investigations. The primary outcome is
death or invasive bacterial infection by 24 weeks.
Other studies are testing alternative interventions de-
signed to reduce early mortality during ART. The
REMSTART study included patients with a CD4 count
under 200 cells/μL in Tanzania and Zambia, who were
individually randomised to standard of care or a com-
plex intervention comprising immediate ART start,
screening for cryptococcal antigen, weekly home visits
from lay workers and screening with Xpert MTB/RIF at
around six weeks [27]. Recruitment to REMSTART is
complete. The REALITY trial is recruiting ART-naïve
adults and children over five years with a CD4 count
under 100 cells/μL in Kenya, Malawi, Uganda and
Zimbabwe [28]. There are three interventions: a) intensi-
fication of ART using raltegravir in addition to a stand-
ard three-drug ART regimen, compared to standard
ART; b) multi-drug prophylaxis against co-infections
using isoniazid, pyridoxine and co-trimoxazole plus
fluconazole for 12 weeks, azithromycin for five days and
single-dose albendazole, compared to co-trimoxazole
alone for 12 weeks followed by isoniazid and pyridox-
ine and c) food supplementation compared to standard
of care.
We planned the TB Fast Track trial to be as pragmatic
(rather than explanatory) as possible, because we wanted
to know if the intervention would improve patient out-
comes under routine conditions in resource-limited set-
tings. Assessing against criteria set out by Thorpe et al.
[29], features of the trial consistent with the pragmatic
end of this spectrum include few exclusion criteria; an
intervention delivered by nurses, as it would be if the
intervention was implemented in practice; a routine
practice comparator, with few study activities in the con-
trol arm likely to alter the standard of care; few study
follow-up visits; a primary outcome, all-cause mortality,
which is objective and clinically meaningful; no special
measures to promote participant adherence and an
intention-to-treat primary analysis.
In a few domains, the trial is less pragmatic: the initial
study intervention (implementation of a management al-
gorithm) is relatively inflexible and undertaken by study
staff, although after the initial management pathway has
been determined (treatment for tuberculosis followed by
ART, or ART alone), further management is by clinic
staff following their usual procedures.
In line with this pragmatic approach, we tried to minim-
ise (in both arms of the study) additional tests for
tuberculosis which are not currently routine practice in
primary care clinics, which would make the intervention
very difficult to replicate in resource-constrained settings.
The exception to this principle was that we requested a
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Table 2 Summary of trials of interventions to reduce early mortality among HIV-positive people starting antiretroviral
therapy
Study Setting Randomisation
level
Study population
(main criteria)
Intervention Outcome(s) Expected
date of
results
PrOMPTa[24] Gabon,
Mozambique,
South Africa,
Uganda
Individual CD4 count <50 and body
mass index <18; no
previous TB treatment;
aged ≥18 years; Sputum
smear negative; and not
fulfilling World Health
Organization criteria for
smear-negative TB.
4-drug TB treatment,
followed by ART within
2 weeks. Comparator: ART
alone
Primary: all-cause mortality
in the first 24 weeks after
initiation of ART, CD4 cell
increase, safety, HIV viral
suppression, TB incidence
after ART initiation
N/A
REMEMBER [25] Brazil, Haiti,
India, Kenya,
Malawi, Peru,
South Africa,
Tanzania,
Zimbabwe
Individual CD4 count <50; aged
≥13 years; Karnofsky ≥30;
no previous TB treatment
(within 96 weeks). Those
with confirmed or
probable TB excluded.
ART initiation within 3 days
and 4-drug TB treatment
within 7 days of ART start.
Comparator: ART initiation
within 3 days
Primary: survival at
24 weeks; survival over
96 weeks; time to AIDS
progression; AIDS-free
survival at 24 and 28 weeks;
HIV viral load at 2, 24 and
48 weeks; safety
May 2016
REMSTART [27] Tanzania,
Zambia
Individual Initially CD4 count <100,
broadened to <200
following slow enrolment;
aged ≥18 years. All
screened for TB at
enrolment with Xpert
MTB/RIF
Rapid initiation of ART,
screening for cryptococcal
antigen, weekly home visits
for 4 weeks by lay workers
and rescreening for TB
using Xpert MTB/RIF at
6 weeks. Comparator:
standard of care
Primary: all-cause mortality
at 12 months, patient
retention, hospital admission,
outpatient attendances, TB,
cryptococcal meningitis, ART
adherence
Dec 2014
REALITY [28] Kenya,
Malawi,
Uganda,
Zimbabwe
Individual CD4 count <100, aged
≥5 years
2x2x2 factorial: a) intensified
ART (triple therapy plus
raltegravir) for 12 weeks;
b) multidrug prophylaxis
against co-infections
(isoniazid, pyridoxine, co-
trimoxazole and fluconazole
for 12 weeks; azithromycin
for 5 days; single dose
albendazole); c) ready-to-use
supplementary food for
12 weeks. Comparator:
standard of care including
co-trimoxazole, with
isoniazid and pyridoxine
after 12 weeks
Primary: mortality over the
first 24 weeks after starting
ART, mortality at 48 weeks
after starting ART, safety,
endpoints relating to the
specific mechanisms of
action of each intervention
Aug 2015
STATIS [26] Cambodia,
Côte d’Ivoire,
Uganda,
Vietnam
Individual CD4 count <100; starting
ART; aged ≥18 years.
Excluded if overt evidence
of TB
Empirical treatment.
Comparator: extensive TB
screening (point of care
urine lipoarabinomannan,
sputum Xpert MTB/RIF,
chest radiograph for all at
enrolment and those with
TB symptoms or signs at all
follow-up visits)
Primary: composite of (i)
24-week all-cause mortality
and (ii) 24-week incidence
of invasive bacterial
infections; incidence of TB;
safety
Jun 2017
TB Fast Track [23] South Africa Clinic CD4 count ≤150; not on
ART and willing to start
ART; aged ≥18 years. No
pre-screening for TB prior
to enrolment
Management strategy to
identify those at highest
risk of TB, so that they can
start TB treatment
immediately, followed by
ART. Comparator: standard
of care
Primary: 6-month mortality,
severe morbidity over
6 months, time to initiation
of ART, retention in ART
care, safety
Dec 2015
aTerminated early due to insufficient enrolment. All CD4 counts are measured in cells/μL ART antiretroviral therapy, TB tuberculosis.
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sputum specimen, processed for smear and culture in a re-
search laboratory, from all participants in the intervention
arm in order to have a gold standard against which to as-
sess our management algorithm. These results are deliv-
ered to clinic staff as soon as they become available. In our
experience to date, they rarely change the patient’s man-
agement since most patients are sputum-smear negative,
and by the time the culture result is available, most
patients have already started tuberculosis treatment. The
disadvantage of this minimalist approach to additional
diagnostic tests is that we do not have a rigorous gold
standard against which to assess the performance of our
algorithm. In addition, if the trial succeeds in reducing
mortality, it may be difficult to assess the relative contri-
butions of prompt tuberculosis treatment and earlier initi-
ation of ART.
A potential challenge to the TB Fast Track trial is the
evolution of South African guidelines for the manage-
ment of HIV-positive patients. The trial was designed
and awarded funding prior to the roll-out of Xpert
MTB/RIF in South Africa. When the trial started, no
trial clinics had access to Xpert MTB/RIF, but by April
2013 all trial clinic guidelines recommended Xpert
MTB/RIF as the first test for people being investigated
for tuberculosis. If this guideline was followed rigorously,
it could potentially increase detection of active tubercu-
losis in all study clinics, which could reduce the effect of
the intervention. In addition, guidance concerning the
initiation of ART has been modified in South Africa,
such that several provinces recommend immediate
(same day) ART initiation among HIV-positive people
who are not taking ART and who have CD4 counts
below 200 cells/μL. The guidance does not make clear
how screening for active tuberculosis should fit into the
process of rapid ART initiation. Rigorous implementa-
tion of this guidance would result in individuals in both
arms of the study starting ART more rapidly than previ-
ously, and thus has the potential to reduce the effect of
the intervention. On the other hand, all changes in
routine practice which are likely to reduce early mortal-
ity are important, and the trial is most useful if it evalu-
ates the intervention against the contemporary standard
of care.
This trial will test whether a management algorithm,
using tests which can be performed in primary care
settings with very few resources, will enable nurses to
identify HIV-positive patients at the highest risk of tu-
berculosis to facilitate prompt treatment, and thus re-
duce early mortality. The intervention will inevitably
result in over-treatment for tuberculosis. We believe this
can be justified in the current context where diagnostic
tests for tuberculosis lack sensitivity amongst the highest
risk patients, and there is consistent evidence that un-
treated tuberculosis is the most important cause of death
in this patient group. There remains an urgent priority
for better diagnostic tests for tuberculosis, encompassing
those with advanced HIV disease and extrapulmonary
tuberculosis, or both, which will render the approach of
empirical treatment unnecessary.
Trial status
The study completed enrolment on 23 December 2014.
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